Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
RYTM Stock Chart & Stats
$107.97
-$0.41(-0.68%)
At close: 4:00 PM EST
$107.97
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$45.91 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)529.70K
Market Cap
$7.21B
Enterprise Value$7.30B
Total Cash (Recent Filing)$416.05M
Total Debt (Recent Filing)$151.00M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 04, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding66,736,050
10 Day Avg. Volume547,186
30 Day Avg. Volume529,695
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)20.75
Price to Sales (P/S)26.24
P/FCF Ratio-29.98
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue41.90
Enterprise Value/Gross Profit46.87
Enterprise Value/Ebitda-43.22
Forecast
1Y Price Target
$142.38Price Target Upside31.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPreliminary Phase 2 results showing BMI and hyperphagia reductions support advancement into a registrational Phase 3 trial in Prader-Willi syndrome, which could de-risk the program and drive valuation upside if replicated in larger studies.
Commercial PreparednessCommercial readiness for a hypothalamic obesity indication, including identified patient cohorts, suggests meaningful revenue upside if regulatory approval is secured and commercialization proceeds as planned.
Pipeline DiversificationDevelopment of an oral MC4R agonist and RM-718 lifecycle programs could broaden treatment options beyond the current therapy, expanding the addressable market and strengthening long-term market share potential.
Bears Say
Disclosure UncertaintyLimited public detail on commercial metrics and pipeline specifics increases information uncertainty, which may pressure the stock until fuller analyst notes or company disclosures are released.
Investor Attention ShiftStrong positive developments among larger biotech peers could draw investor attention and capital away, potentially weighing on the company's near-term share performance despite its own progress.
Launch Adoption RiskHypothalamic obesity launch could experience slower uptake due to a lack of dedicated treatment centers and less-engaged advocacy networks, which may constrain early commercial momentum.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $45.91 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $7.21B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.708 by -$0.112.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.81.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 66,736,050 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.708. Following the earnings report the stock price went down -7.693%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.38 (31.87% Upside)
$142.38 (31.87% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 123.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.27%
12-Months-Change
Fundamentals
Return on Equity
-240.36%
Trailing 12-Months
Asset Growth
39.41%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM Company Deck
RYTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Rhythm Pharmaceuticals demonstrated strong revenue growth and regulatory progress, particularly for IMCIVREE in hypothalamic obesity. While international revenue faced challenges, the company's successful equity offering and promising data in BBS highlight a positive outlook. R&D costs are rising, but the overall sentiment remains optimistic.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$142.38
▲(31.87% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
Currently, No data available
---